Percutaneous Versus EUS FNAC in Pancreatic Masses
Percutaneous Versus Endoscopic Guided Fine Needle Aspiration Cytology in Diagnosis of Pancreatic Masses
1 other identifier
interventional
50
0 countries
N/A
Brief Summary
We aim to evaluate the role of Ultrasound-guided (USG) fine needle aspiration cytology (FNAC) in diagnosis of pancreatic masses compared to endoscopic ultrasound (EUS) guided fine needle aspiration cytology (FNAC).
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Dec 2021
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
November 4, 2020
CompletedFirst Posted
Study publicly available on registry
November 10, 2020
CompletedStudy Start
First participant enrolled
December 1, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
March 1, 2023
CompletedJune 14, 2021
June 1, 2021
1 year
November 4, 2020
June 11, 2021
Conditions
Outcome Measures
Primary Outcomes (1)
Yield, as defined by the percentage of patients in whom a histologically interpretable specimen will be retrieved by Trans abdominal US-FNAC. diagnostic accuracy
Percutaneous US guided FNAC technique
intraopeatve
Secondary Outcomes (1)
Yield, as defined by the percentage of patients in whom a histologically interpretable specimen will be retrieved by EUS-FNAC. diagnostic accuracy
intraoperative
Study Arms (2)
Percutaneous US guided FNAC in pancreatic masses
ACTIVE COMPARATOREUS guided FNAC in pancreatic masses
ACTIVE COMPARATORInterventions
Eligibility Criteria
You may qualify if:
- Patients in different sex \& age groups with pancreatic masses
You may not qualify if:
- Any general contraindications for FNAC or EUS in some cases as Coagulopathy with INR \>1.5 or platelet count \<50,000/mmc, Antithrombotic therapy.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Related Publications (2)
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015 Jan-Feb;65(1):5-29. doi: 10.3322/caac.21254. Epub 2015 Jan 5.
PMID: 25559415BACKGROUNDEgawa S, Toma H, Ohigashi H, Okusaka T, Nakao A, Hatori T, Maguchi H, Yanagisawa A, Tanaka M. Japan Pancreatic Cancer Registry; 30th year anniversary: Japan Pancreas Society. Pancreas. 2012 Oct;41(7):985-92. doi: 10.1097/MPA.0b013e318258055c.
PMID: 22750974BACKGROUND
Related Links
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NON RANDOMIZED
- Masking
- NONE
- Purpose
- DIAGNOSTIC
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- Principal Investigator
Study Record Dates
First Submitted
November 4, 2020
First Posted
November 10, 2020
Study Start
December 1, 2021
Primary Completion
December 1, 2022
Study Completion
March 1, 2023
Last Updated
June 14, 2021
Record last verified: 2021-06